Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2010.,” Morb. Mortal. Wkly. Rep. Surveill. Summ. Wash. DC 2002, vol. 63, no. 2, pp. 1–21, Mar. 2014.
Chahrour M, O’Roak BJ, Santini E, Samaco RC, Kleiman RJ, Manzini MC. Current perspectives in autism disorder: from genes to therapy. J. Neurosci. 2016;36(45):11402.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zafeiriou DI, Ververi A, Vargiami E. Childhood autism and associated comorbidities. Brain Dev. 29(5):257–72.
Buescher AVS, Cidav Z, Knapp M, Mandell DS. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–8.
Article
PubMed
Google Scholar
LeClerc S, Easley D. Pharmacological therapies for autism spectrum disorder: a review. Pharm Ther. 2015;40(6):389–97.
Google Scholar
Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry. 2006;12(1):2–22.
Article
PubMed
CAS
Google Scholar
Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on the path to precision medicine. Lancet Neurol. 2015;14(11):1109–20.
Article
PubMed
PubMed Central
Google Scholar
Careaga M, Murai T, Bauman MD. Maternal immune activation and autism spectrum disorder: from rodents to nonhuman and human primates. Biol Psychiatry. 2017;81(5):391–401.
Article
PubMed
CAS
Google Scholar
Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. Mol. Autism. 2017;8(1):13.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tordjman S, et al. Gene × Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. Front Psychiatry. 2014;5:53.
Article
PubMed
PubMed Central
Google Scholar
Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1(9):727–30.
Article
PubMed
CAS
Google Scholar
Templeton NS. Gene and cell therapy: therapeutic mechanisms and strategies. 4th ed: CRC Press; 2015, Boca Raton, FL.
Naldini L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351–60.
Article
PubMed
CAS
Google Scholar
Hoy SM. Nusinersen: first global approval. Drugs. 2017;77(4):473–9.
Article
PubMed
CAS
Google Scholar
Shaberman B. A retinal research nonprofit paves the way for commercializing gene therapies. Hum Gene Ther. 2017;28(12):1118–21.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–22.
Article
PubMed
CAS
Google Scholar
Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018;7(1):15–28.
Article
PubMed
Google Scholar
Sztainberg Y, Zoghbi HY. Lessons learned from studying syndromic autism spectrum disorders. Nat Neurosci. 2016;19(11):1408–17.
Article
PubMed
CAS
Google Scholar
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–8.
Article
PubMed
CAS
Google Scholar
Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet. 1997;15(1):70–3.
Article
PubMed
CAS
Google Scholar
Splawski I, et al. CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 119(1):19–31.
van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–8.
Article
PubMed
CAS
Google Scholar
Verkerk AJ, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–14.
Article
PubMed
CAS
Google Scholar
Yuen RKC, et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat Neurosci. 2017;20(4):602–11.
Article
PubMed Central
CAS
Google Scholar
De Rubeis S, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515(7526):209–15.
Article
PubMed
PubMed Central
CAS
Google Scholar
Iossifov I, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216–21.
Article
PubMed
PubMed Central
CAS
Google Scholar
Iossifov I, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74(2):285–99.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jiang Y, et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet. 2013;93(2):249–63.
Article
PubMed
PubMed Central
CAS
Google Scholar
Neale BM, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485(7397):242–5.
Article
PubMed
PubMed Central
CAS
Google Scholar
O’Roak BJ, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sanders SJ, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485(7397):237–41.
Article
PubMed
PubMed Central
CAS
Google Scholar
Yuen RKC, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat Med. 2015;21(2):185–91.
Article
PubMed
CAS
Google Scholar
Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 2012;4(3)
Kleijer KTE, et al. Neurobiology of autism gene products: towards pathogenesis and drug targets. Psychopharmacology. 2014;231(6):1037–62.
Article
PubMed
CAS
Google Scholar
Loke YJ, Hannan AJ, Craig JM. The role of epigenetic change in autism spectrum disorders. Front Neurol. 2015;6:107.
Article
PubMed
PubMed Central
Google Scholar
Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun. 2012;26(3):383–92.
Article
PubMed
CAS
Google Scholar
Beversdorf DQ, MISSOURI AUTISM SUMMIT CONSORTIUM. Phenotyping, etiological factors, and biomarkers: toward precision medicine in autism spectrum disorders. J Dev Behav Pediatr. 2016;37(8):659–73.
Article
PubMed
PubMed Central
Google Scholar
Berry-Kravis EM, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci. Transl. Med. 2012;4(152):152ra127.
Article
PubMed
CAS
Google Scholar
Denayer T, Stöhr T, Van Roy M. Animal models in translational medicine: validation and prediction. New Horiz Transl Med. 2014;2(1):5–11.
Google Scholar
Huerta M, Lord C. Diagnostic evaluation of autism spectrum disorders. Pediatr Clin N Am. 2012;59(1):103–11.
Article
Google Scholar
Bekoff M. Animal Emotions: Exploring Passionate Natures: current interdisciplinary research provides compelling evidence that many animals experience such emotions as joy, fear, love, despair, and grief—we are not alone. BioScience. 2000;50(10):861–70.
Article
Google Scholar
Stafstrom CE, Benke TA. Autism and epilepsy: exploring the relationship using experimental models. Epilepsy Curr. 2015;15(4):206–10.
Article
PubMed
PubMed Central
Google Scholar
Crawley JN. Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin Neurosci. 2012;14(3):293–305.
PubMed
PubMed Central
Google Scholar
Hulbert SW, Jiang Y. Monogenic mouse models of autism spectrum disorders: common mechanisms and missing links. Neuroscience. 2016;321:3–23.
Article
PubMed
CAS
Google Scholar
Persico AM, Napolioni V. Autism genetics. Behav Brain Res. 2013;251:95–112.
Article
PubMed
Google Scholar
Kim H, Lim C-S, Kaang B-K. Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder. Behav. Brain Funct. 2016;12(1):3.
Article
PubMed
PubMed Central
CAS
Google Scholar
D’Mello AM, Stoodley CJ. Cerebro-cerebellar circuits in autism spectrum disorder. Front Neurosci. 2015;9:408.
PubMed
PubMed Central
Google Scholar
Li J, et al. Integrated systems analysis reveals a molecular network underlying autism spectrum disorders. Mol. Syst. Biol. 2014;10(12):774.
Article
PubMed
PubMed Central
CAS
Google Scholar
Petrelli F, Pucci L, Bezzi P. Astrocytes and microglia and their potential link with autism spectrum disorders. Front Cell Neurosci. 2016;10:21.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, Monteggia LM. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol Psychiatry. 2006;59(5):468–76.
Article
PubMed
CAS
Google Scholar
Skefos J, et al. Regional alterations in purkinje ell density in patients with autism. PLoS ONE. 2014;9(2):e81255.
Article
PubMed
PubMed Central
CAS
Google Scholar
D’Mello AM, Crocetti D, Mostofsky SH, Stoodley CJ. Cerebellar gray matter and lobular volumes correlate with core autism symptoms. NeuroImage Clin. 2015;7:631–9.
Article
PubMed
PubMed Central
Google Scholar
Stoodley CJ, et al. Altered cerebellar connectivity in autism and cerebellar-mediated rescue of autism-related behaviors in mice. Nat Neurosci. 2017;20(12):1744–51.
Article
PubMed
PubMed Central
CAS
Google Scholar
Auerbach BD, Osterweil EK, Bear MF. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature. 2011;480(7375):63–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dolen G, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56(6):955–62.
Article
PubMed
PubMed Central
CAS
Google Scholar
Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science. 2007;315(5815):1143–7.
Article
PubMed
Google Scholar
Ehninger D, et al. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med. 2008;14(8):843–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dolan BM, et al. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc Natl Acad Sci U S A. 2013;110(14):5671–6.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sztainberg Y, et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides. Nature. 2015;528(7580):123–6.
PubMed
PubMed Central
CAS
Google Scholar
Mei Y, et al. Adult restoration of Shank3 expression rescues selective autistic-like phenotypes. Nature. 2016;530(7591):481–4.
Article
PubMed
PubMed Central
CAS
Google Scholar
Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Small Mol. Neurol. Disord. 2017;120(Supplement C):63–80.
CAS
Google Scholar
Gray SJ. Gene therapy and neurodevelopmental disorders. Neurodev. Disord. 2013;68(Supplement C):136–42.
CAS
Google Scholar
Modlich U, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 1919–1928;17(11)
Hacein-Bey-Abina S, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–42.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27(7):478–96.
Article
PubMed
PubMed Central
CAS
Google Scholar
Taymans J-M, et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther. 2007;18(3):195–206.
Article
PubMed
CAS
Google Scholar
Aschauer DF, Kreuz S, Rumpel S. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLOS ONE. 2013;8(9):e76310.
Article
PubMed
PubMed Central
CAS
Google Scholar
Powell SK, Rivera-Soto R, Gray SJ. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med. 2015;19(102):49–57.
PubMed
PubMed Central
Google Scholar
Vite CH, Passini MA, Haskins ME, Wolfe JH. Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 2003;10(22):1874–81.
Article
PubMed
CAS
Google Scholar
S. Palfi et al., “Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial,” The Lancet, 383, 9923, 1138–1146. 2014
Katz DM, et al. Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 39(2):100–13.
Bruno JL, Hosseini SMH, Saggar M, Quintin E-M, Raman MM, Reiss AL. Altered brain network segregation in fragile X syndrome revealed by structural connectomics. Cereb Cortex. 2017;27(3):2249–59.
PubMed
Google Scholar
Dehay B, Dalkara D, Dovero S, Li Q, Bezard E. Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. 2012;2:253.
Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotech. 2016;34(2):204–9.
Article
CAS
Google Scholar
Boutin S, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704–12.
Article
PubMed
CAS
Google Scholar
Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19(6):1058–69.
Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36.
Article
PubMed
PubMed Central
CAS
Google Scholar
Geisler A, Fechner H. MicroRNA-regulated viral vectors for gene therapy. World J Exp Med. 2016;6(2):37–54.
Article
PubMed
PubMed Central
Google Scholar
Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol. 2005;79(15):9933–44.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tse LV, et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci. 2017;114(24):E4812–21.
Article
PubMed
PubMed Central
CAS
Google Scholar
Federici T, et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther. 2012;19(8):852–9.
Article
PubMed
CAS
Google Scholar
Schuster DJ, et al. Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat. 2014;8:42.
PubMed
PubMed Central
Google Scholar
Samaranch L, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 2012;23(4):382–9.
Article
PubMed
CAS
Google Scholar
Saraiva J, Nobre RJ, Pereira de Almeida L. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9. J. Controlled Release. 2016;241(Supplement C):94–109.
Article
CAS
Google Scholar
Mussche S, et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther. 2013;24(2):209–19.
Article
PubMed
CAS
Google Scholar
Gadalla KK, et al. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther. 2013;21(1):18–30.
Article
PubMed
CAS
Google Scholar
Matagne V, et al. A codon-optimized Mecp2 transgene corrects breathing deficits and improves survival in a mouse model of Rett syndrome. Neurobiol Dis. 2017;99:1–11.
Article
PubMed
CAS
Google Scholar
Garg SK, et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J. Neurosci. 2013;33(34):13612.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tillotson R, et al. Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature. 2017;550:398.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zeier Z, Kumar A, Bodhinathan K, Feller JA, Foster TC, Bloom DC. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther. 2009;16(9):1122–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gholizadeh S, Arsenault J, Xuan ICY, Pacey LK, Hampson DR. Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014;39(13):3100–11.
Article
CAS
Google Scholar
Prabhakar S, et al. Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiol Dis. 2015;82:22–31.
Article
PubMed
PubMed Central
CAS
Google Scholar
Robinson L, et al. Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome. Brain. 2012;135(9):2699–710.
Article
PubMed
PubMed Central
Google Scholar
Gadalla KK, et al. Development of a novel AAV gene therapy cassette with improved safety features and efficacy in a mouse model of Rett syndrome. Mol Ther Methods Clin Dev. 2017;5:180–90.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kyle SM, Saha PK, Brown HM, Chan LC, Justice MJ. MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex. Hum Mol Genet. 2016;25(14):3029–41.
PubMed
PubMed Central
CAS
Google Scholar
Arsenault J, et al. FMRP expression levels in mouse central nervous system neurons determine behavioral phenotype. Hum Gene Ther. 2016;27(12):982–96.
Article
PubMed
PubMed Central
CAS
Google Scholar
Friez MJ, et al. Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics. 2006;118(6):e1687.
Article
PubMed
Google Scholar
Meins M, et al. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J Med Genet. 2005;42(2):e12.
Article
PubMed
PubMed Central
CAS
Google Scholar
Van Esch H, et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet. 2005;77(3):442–53.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lyon MF. X-chromosome inactivation and human genetic disease. Acta Paediatr Oslo Nor 1992 Suppl. 2002;91(439):107–12.
CAS
Google Scholar
Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125–40.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015;16(9):543–52.
Article
PubMed
PubMed Central
CAS
Google Scholar
Scoto M, Finkel RS, Mercuri E, Muntoni F. Therapeutic approaches for spinal muscular atrophy (SMA). Gene Ther. 2017;24(9):514–9.
Article
PubMed
CAS
Google Scholar
Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 16, 10:837–47.
Sztainberg Y, et al. Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligos. Nature. 2015;528(7580):123–6.
PubMed
PubMed Central
CAS
Google Scholar
Krishnan V, et al. Autism gene Ube3a and seizures impair sociability by repressing VTA Cbln1. Nature. 2017;543(7646):507–12.
Article
PubMed
PubMed Central
CAS
Google Scholar
Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by reduction of a long non-coding RNA. Nature. 2015;518(7539):409–12.
Article
PubMed
CAS
Google Scholar
Silva-Santos S, et al. Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model. J Clin Invest. 2015;125(5):2069–76.
Article
PubMed
PubMed Central
Google Scholar
Watts JK, Corey DR. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic. J Pathol. 2012;226(2):365–79.
Article
PubMed
CAS
Google Scholar
Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24(3):430–46.
Article
PubMed
PubMed Central
CAS
Google Scholar
Peng R, Lin G, Li J. Potential pitfalls of CRISPR/Cas9-mediated genome editing. FEBS J. 2016;283(7):1218–31.
Article
PubMed
CAS
Google Scholar
Wang L, et al. In vivo delivery systems for therapeutic genome editing. Int J Mol Sci. 2016;17(5):626.
Article
PubMed Central
CAS
Google Scholar
Staahl BT, et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat Biotech. 2017;35(5):431–4.
Article
CAS
Google Scholar
Lim ET, et al. Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. Nat Neurosci. 2017;20:1217.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gkogkas CG, et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature. 2013;493(7432):371–7.
Article
PubMed
CAS
Google Scholar
Südhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455(7215):903–11.
Article
PubMed
PubMed Central
CAS
Google Scholar
Singh SK, Eroglu C. Neuroligins provide molecular links between syndromic and nonsyndromic autism. Sci Signal. 2013;6(283):re4.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sato A. mTOR, a potential target to treat autism spectrum disorder. CNS Neurol Disord Drug Targets. 2016;15(5):533–43.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sato A, et al. “Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex,” Nat Commun. 2012;3:1292.
Baudouin SJ, et al. Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science. 2012;338(6103):128–32.
Article
PubMed
CAS
Google Scholar
Novarino G, et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science. 2012;338(6105):394–7.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tarlungeanu DC, et al. Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder. Cell. 2016;167(6):1481–1494.e18.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sethna F, Moon C, Wang H. From FMRP function to potential therapies for fragile X syndrome. Neurochem Res. 2014;39(6):1016–31.
Article
PubMed
CAS
Google Scholar
Richards C, Jones C, Groves L, Moss J, Oliver C. Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2015;2(10):909–16.
Article
PubMed
Google Scholar
Guy J, Cheval H, Selfridge J, Bird A. The role of MeCP2 in the brain. Annu Rev Cell Dev Biol. 2011;27(1):631–52.
Article
PubMed
CAS
Google Scholar
Ramocki MB, et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MECP2 duplication syndrome. Ann Neurol. 2009;66(6):771–82.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci. 2002;99(21):13571–6.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tomaic V, Banks L. Angelman syndrome-associated ubiquitin ligase UBE3A/E6AP mutants interfere with the proteolytic activity of the proteasome. Cell Death Dis. 2015;6:e1625.
Article
PubMed
PubMed Central
CAS
Google Scholar
Betancur C, Sakurai T, Buxbaum JD. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 32(7):402–12.
Ye H, Liu J, Wu JY. Cell adhesion molecules and their involvement in autism spectrum disorder. Neurosignals. 2010;18(2):62–71.
Article
PubMed
CAS
Google Scholar
Ting JT, Peça J, Feng G. Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu Rev Neurosci. 2012;35(1):49–71.
Article
PubMed
CAS
Google Scholar
Zheng F, et al. Evidence for association between Disrupted-in-schizophrenia 1 (DISC1) gene polymorphisms and autism in Chinese Han population: a family-based association study. Behav. Brain Funct. 2011;7(1):14.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chen J, Yu S, Fu Y, Li X. Synaptic proteins and receptors defects in autism spectrum disorders. Front Cell Neurosci. 2014;8:276.
PubMed
PubMed Central
Google Scholar
Rojas DC. The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J Neural Transm Vienna Austria 1996. 2014;121(8):891–905.
CAS
Google Scholar
Platt RJ, et al. Chd8 mutation leads to autistic-like behaviors and impaired striatal circuits. Cell Rep. 19(2):335–50.
Breuss MW, Gleeson JG. When size matters: CHD8 in autism. Nat Neurosci. 2016;19(11):1430–2.
Article
PubMed
CAS
Google Scholar